Delving into the Latest Updates on Quadrivalent Subunit Influenza Virus Vaccine(Seqirus) with Synapse

Overview

Basic Info

Drug Type

Prophylactic vaccine, Genetically engineered subunit vaccine

Synonyms-

Target-

Action

stimulants

Mechanism

Immunostimulants

Therapeutic Areas

Infectious DiseasesRespiratory Diseases

Active Indication-

Inactive Indication

Influenza, Human

Originator Organization

Seqirus GmbH

Active Organization-

Inactive Organization

Seqirus GmbH

License Organization-

Drug Highest PhasePendingPhase 3

First Approval Date-

Regulation-

Login to view timeline

A Phase III, Randomized, Observer Blind, Multicenter Study to Evaluate the Safety and Immunogenicity of Repeated Exposure to Either the Same or Alternate Type of Vaccine, Adjuvanted or Non-adjuvanted Quadrivalent Subunit Influenza Virus Vaccine (aQIV or QIV), Administered to Subjects Previously Vaccinated in Trial V118_05 (NCT01964989)

Safety, Immunogenicity of an Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine Compared to Non-Adjuvanted Comparator Influenza Vaccine in Children Previously vaccinated in Trial V118_05. Subjects will receive either the Same or Alternate Type of Vaccine.

Start Date29 Jan 2016

Sponsor / Collaborator

Seqirus GmbH

NCT01964989

/ CompletedPhase 3

A Phase III, Stratified, Randomized, Observer Blind, Controlled, Multicenter Clinical Study to Evaluate the Safety, Immunogenicity and Efficacy of an Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine Compared to Non-Adjuvanted Comparator Influenza Vaccine in Children ≥6 to < 72 Months of Age.

Safety, Immunogenicity and Efficacy of an Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine Compared to Non-Adjuvanted Comparator Influenza Vaccine in Children ≥6 to <72 Months of Age. The study was conducted during the 2013/2014 and 2014/2015 northern hemisphere influenza season.

Start Date01 Nov 2013

Sponsor / Collaborator

Seqirus GmbH

100 Clinical Results associated with Quadrivalent Subunit Influenza Virus Vaccine(Seqirus)

Login to view more data

100 Translational Medicine associated with Quadrivalent Subunit Influenza Virus Vaccine(Seqirus)

Login to view more data

100 Patents (Medical) associated with Quadrivalent Subunit Influenza Virus Vaccine(Seqirus)

Login to view more data

100 Deals associated with Quadrivalent Subunit Influenza Virus Vaccine(Seqirus)

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Influenza, Human	Phase 3	United States	Seqirus GmbH	01 Nov 2013
Influenza, Human	Phase 3	Canada	Seqirus GmbH	01 Nov 2013
Influenza, Human	Phase 3	Finland	Seqirus GmbH	01 Nov 2013
Influenza, Human	Phase 3	Italy	Seqirus GmbH	01 Nov 2013
Influenza, Human	Phase 3	Mexico	Seqirus GmbH	01 Nov 2013
Influenza, Human	Phase 3	Philippines	Seqirus GmbH	01 Nov 2013
Influenza, Human	Phase 3	Poland	Seqirus GmbH	01 Nov 2013
Influenza, Human	Phase 3	Spain	Seqirus GmbH	01 Nov 2013
Influenza, Human	Phase 3	Taiwan Province	Seqirus GmbH	01 Nov 2013
Influenza, Human	Phase 3	Thailand	Seqirus GmbH	01 Nov 2013

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02583256 (CTgov)	Phase 3	Influenza, Human	1,601	Adjuvanted QIV (aQIV) (aQIV/aQIV)	paojfickhg(sbgjoxbrad) = jlccuuayye mjmkzgwuka (vucwrhkjsp, lrwxkufaco - bzdrgemikn) View more	-	24 Apr 2019
				Non-adjuvanted QIV (aQIV/QIV)	paojfickhg(sbgjoxbrad) = oxwlinqkkw mjmkzgwuka (vucwrhkjsp, qejqpwfkaf - catdizonjt) View more